Philadelphia medical centers on Friday announced a new collaboration that will use precision medicine technology to further brain tumor research.
The Philadelphia Coalition for a Cure, or PC4C, will use tissue and blood samples from brain cancer patients for genomic and proteomic analysis, according to press releases. In an early research initiative, coalition members will use GPS Cancer, a comprehensive molecular test that sequences the patient's whole genetic code. The coalition will also create a large storage facility for tissue, genomic and clinical data.
"The potential benefits of this type of tissue analysis are profound," David Andrews, chief of neuro-oncology at Thomas Jefferson University, said in a release. "The information obtained may ultimately be able to determine individualized treatment strategies and identify patients for active clinical trials of new therapies."
Besides Jefferson's Sidney Kimmel Medical College, the PC4C members are: Children's Hospital of Philadelphia; Lewis Katz School of Medicine at Temple University; Perelman School of Medicine at the University of Pennsylvania; Drexel University College of Medicine; Cooper Medical School of Rowan University in Camden, NJ; the Hyundai Cancer Institute at the Children's Hospital of Orange County.